Cargando…

P684: A MULTICENTER RETROSPECTIVE STUDY IN CHINA: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH CML-CP TREATED WITH DIFFERENT TYROSINE KINASE INHIBITORS

Detalles Bibliográficos
Autores principales:	Huang, Jian, Zhang, Xinlu, Feng, Weiying, Qian, Honglan, Yu, Chen, Liu, Lirong, Chen, Dan, Zhu, Xiaoqiong, Wang, Huafeng, Yang, Xiudi, Zhu, Jingjing, Wu, Dijiong, Zhou, Mei, Lu, Ying, Wang, Yi, Tong, Hongyan, Jin, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429670/ http://dx.doi.org/10.1097/01.HS9.0000969640.53011.8d

Ejemplares similares

P664: REAL-WORLD ANALYSIS OF MUTATION CHARACTERISTICS AND CLINICAL OUTCOMES IN 343 CHRONIC MYELOID LEUKEMIA PATIENTS WITH BCR::ABL KINASE DOMAIN MUTATIONS
por: Hu, Shiwei, et al.
Publicado: (2023)

CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice
por: Liu, Jiandong, et al.
Publicado: (2023)

684. WE-Heraeus-Seminar
por: Vacchini, Bassano, et al.
Publicado: (2019)

SUN-684 The Dance of Diabetes
por: Thakkar, Aditi, et al.
Publicado: (2020)

684. Risk Stacking for Pneumococcal Disease in Costa Rica
por: Chaverri-Murillo, Jorge, et al.
Publicado: (2018)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Deterioration of Parkinson's disease during hospitalization: survey of 684 patients
por: Gerlach, Oliver HH, et al.
Publicado: (2012)

MON-684 Neuroglycopenia: Avoiding Bias in Patients with Acute Psychosis
por: Otuonye, Gene Chibuchim, et al.
Publicado: (2020)

684. Diagnostic Yield of Echocardiography in Coagulase Negative Staphylococcus Bacteremia
por: Nagarakanti, Sandhya, et al.
Publicado: (2021)

T315I(+) tyrosine-kinase independent CML cells resistance
por: Nicolini, Franck Emmanuel, et al.
Publicado: (2017)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Newborn Screening for Pompe Disease in Illinois: Experience with 684,290 Infants
por: Burton, Barbara K., et al.
Publicado: (2020)

Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
por: Wang, Jingqiu, et al.
Publicado: (2020)

684 A Festering Affliction: Etiology and Clinical Manifestations of Thorn-Associated Infections
por: Simmons, Sierra, et al.
Publicado: (2014)

Adult perioperative cardiac arrest: An overview of 684 cases reported to webAIRS
por: Bright, Matthew R, et al.
Publicado: (2023)

SAT-684 A Deadly Triad: Coexistence of Acute Pancreatitis, Hypertryglyceridemia and Diabetic Ketoacidosis
por: Torres Torres, Marina T, et al.
Publicado: (2020)

FRI684 So Strong Yet So Fragile: Bilateral Periprosthetic Fractures On Denosumab
por: Syeda, Asma, et al.
Publicado: (2023)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
por: Etienne, Gabriel, et al.
Publicado: (2020)

Treatment-free remission: A new goal for all chronic phase (CP)-CML patients
por: Rea, Delphine
Publicado: (2018)

Draft Genome Sequence of Saccharomyces cerevisiae Strain P-684, Isolated from Prunus verecunda
por: Takahashi, Hiro, et al.
Publicado: (2020)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

PT684. Treatment with rapamycin improves deficits of social interaction in the mice exposed in utero to valproic acid
por: Murakami-Kotajima, Hiroko, et al.
Publicado: (2016)

Oral potentially malignant disorders: clinical-pathological study of 684 cases diagnosed in a Brazilian population
por: Pires, Fábio Ramôa, et al.
Publicado: (2020)

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
por: Eadie, Laura N., et al.
Publicado: (2016)

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
por: Cerveira, Nuno, et al.
Publicado: (2018)

Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells
por: Trinh, Anne, et al.
Publicado: (2021)

Cytogenetic study in CML
por: Subramanian, P.G.
Publicado: (2012)

CML: Evolution and design
por: Murray-Rust, Peter, et al.
Publicado: (2011)

An attenuated strain of Bacillus anthracis (CDC 684) has a large chromosomal inversion and altered growth kinetics
por: Okinaka, Richard T, et al.
Publicado: (2011)

684. Characteristics of Patients with Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
por: Guh, Alice, et al.
Publicado: (2023)

Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics
por: Carpiuc, Kimbach Tran, et al.
Publicado: (2010)

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
por: Vaidya, Shantashri, et al.
Publicado: (2015)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
por: Malyukova, Alena, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy
por: Gómez-Castañeda, Eduardo, et al.
Publicado: (2022)

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
por: Sanchez, María Belén, et al.
Publicado: (2023)

P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
por: Hughes, Timothy, et al.
Publicado: (2023)

A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer
por: Guo, Yufeng, et al.
Publicado: (2021)

Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c9cb1lkcsot6eo44tuvvea4tgl